Last reviewed · How we verify
Biologic TNFi
A TNF inhibitor biologic that blocks tumor necrosis factor (TNF) to reduce inflammatory immune responses.
A TNF inhibitor biologic that blocks tumor necrosis factor (TNF) to reduce inflammatory immune responses. Used for Rheumatoid arthritis, Inflammatory bowel disease, Psoriasis.
At a glance
| Generic name | Biologic TNFi |
|---|---|
| Also known as | Humira (Adalimumab) |
| Sponsor | Pfizer |
| Drug class | TNF inhibitor |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
TNF inhibitors are biologics that bind to and neutralize TNF-alpha, a key pro-inflammatory cytokine. By blocking TNF signaling, these agents suppress excessive immune activation and inflammation, making them effective in autoimmune and inflammatory diseases. Pfizer's TNFi candidate likely uses a monoclonal antibody or fusion protein approach to achieve TNF inhibition.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease
- Psoriasis
- Ankylosing spondylitis
Common side effects
- Infections (including serious infections)
- Injection site reactions
- Upper respiratory tract infections
- Tuberculosis reactivation
- Headache
Key clinical trials
- Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (NA)
- A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
- RA-PRO PRAGMATIC TRIAL (PHASE3)
- An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data From the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU)
- People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT)
- Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biologic TNFi CI brief — competitive landscape report
- Biologic TNFi updates RSS · CI watch RSS
- Pfizer portfolio CI